Literature DB >> 27465410

Association between major depression and cardiovascular risk: the role of antidepressant medication.

Linn K Kuehl1, Christoph Muhtz2, Kim Hinkelmann3, Lucia Dettenborn4, Katja Wingenfeld3, Carsten Spitzer5, Christian Otte3.   

Abstract

RATIONALE AND
OBJECTIVES: Major depressive disorder (MDD) is associated with an increased risk for cardiovascular disease (CVD). Apart from biological and life style factors, the use of antidepressants and their potentially adverse effects might contribute to the increased CVD risk. Therefore, we compared cardiovascular risk profiles between relatively young depressed patients without CVD with and without antidepressant medication and healthy participants.
METHODS: We investigated 44 depressed patients (with antidepressants N = 20 (13 women), mean age 43.2 years; without antidepressants N = 24 (15 women), mean age 40.0) and 41 healthy participants (matched for sex, age, education). As markers of CVD risk, blood pressure, body mass index (BMI), and plasma levels of fasting glucose, cholesterol, low density lipoprotein (LDL), high density lipoprotein (HDL), and high sensitivity C-reactive protein (h-CRP) were measured.
RESULTS: We found significant differences between groups for BMI (p < .01), systolic (p = .02) and diastolic blood pressure (p < .01), and glucose (p < .001). Post hoc analyses indicated differences between both patient groups compared to the healthy control group, but not between patients groups. Further controlling for BMI diminished the effect of diagnosis on blood pressure; however, this was not the case for glucose level. There were no between-group differences in cholesterol, LDL, HDL, and h-CRP.
CONCLUSIONS: We found a clearly increased CVD risk in this group of rather young depressed patients. Importantly, there was no significant difference in CVD risk between patients with vs. without antidepressants. This suggests that major depression per se and not antidepressant medication is associated with increased CVD risk.

Entities:  

Keywords:  Antidepressants; Blood pressure; Body mass index; Cardiovascular risk; Glucose; Major depression

Mesh:

Substances:

Year:  2016        PMID: 27465410     DOI: 10.1007/s00213-016-4361-3

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  51 in total

1.  Longitudinal evidence for unfavorable effects of antidepressants on heart rate variability.

Authors:  Carmilla M M Licht; Eco J C de Geus; Richard van Dyck; Brenda W J H Penninx
Journal:  Biol Psychiatry       Date:  2010-09-16       Impact factor: 13.382

2.  Effects of depression, anxiety, comorbidity, and antidepressants on resting-state heart rate and its variability: an ELSA-Brasil cohort baseline study.

Authors:  Andrew H Kemp; Andre R Brunoni; Itamar S Santos; Maria A Nunes; Eduardo M Dantas; Roberta Carvalho de Figueiredo; Alexandre C Pereira; Antonio L P Ribeiro; José G Mill; Rodrigo V Andreão; Julian F Thayer; Isabela M Benseñor; Paulo A Lotufo
Journal:  Am J Psychiatry       Date:  2014-10-31       Impact factor: 18.112

3.  Antidepressant use and risk of out-of-hospital cardiac arrest: a nationwide case-time-control study.

Authors:  P Weeke; A Jensen; F Folke; G H Gislason; J B Olesen; C Andersson; E L Fosbøl; J K Larsen; F K Lippert; S L Nielsen; T Gerds; P K Andersen; J K Kanters; H E Poulsen; S Pehrson; L Køber; C Torp-Pedersen
Journal:  Clin Pharmacol Ther       Date:  2012-05-16       Impact factor: 6.875

4.  Prevalence of metabolic syndrome in subjects with melancholic and non-melancholic depressive symptoms. A Finnish population-based study.

Authors:  Jussi Seppälä; Mauno Vanhala; Hannu Kautiainen; Johan Eriksson; Olli Kampman; Pekka Mäntyselkä; Heikki Oksa; Yrjö Ovaskainen; Merja Viikki; Hannu Koponen
Journal:  J Affect Disord       Date:  2011-11-25       Impact factor: 4.839

5.  Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) trial.

Authors:  François Lespérance; Nancy Frasure-Smith; Diana Koszycki; Marc-André Laliberté; Louis T van Zyl; Brian Baker; John Robert Swenson; Kayhan Ghatavi; Beth L Abramson; Paul Dorian; Marie-Claude Guertin
Journal:  JAMA       Date:  2007-01-24       Impact factor: 56.272

6.  Prognosis of patients taking selective serotonin reuptake inhibitors before coronary artery bypass grafting.

Authors:  Glen L Xiong; Wei Jiang; Robert Clare; Linda K Shaw; Peter K Smith; Kenneth W Mahaffey; Christopher M O'Connor; K Ranga R Krishnan; L Kristin Newby
Journal:  Am J Cardiol       Date:  2006-05-05       Impact factor: 2.778

7.  Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study.

Authors:  Martin J O'Donnell; Denis Xavier; Lisheng Liu; Hongye Zhang; Siu Lim Chin; Purnima Rao-Melacini; Sumathy Rangarajan; Shofiqul Islam; Prem Pais; Matthew J McQueen; Charles Mondo; Albertino Damasceno; Patricio Lopez-Jaramillo; Graeme J Hankey; Antonio L Dans; Khalid Yusoff; Thomas Truelsen; Hans-Christoph Diener; Ralph L Sacco; Danuta Ryglewicz; Anna Czlonkowska; Christian Weimar; Xingyu Wang; Salim Yusuf
Journal:  Lancet       Date:  2010-06-17       Impact factor: 79.321

8.  Depression as an aetiologic and prognostic factor in coronary heart disease: a meta-analysis of 6362 events among 146 538 participants in 54 observational studies.

Authors:  Amanda Nicholson; Hannah Kuper; Harry Hemingway
Journal:  Eur Heart J       Date:  2006-11-02       Impact factor: 29.983

9.  Antidepressant use and risk of incident cardiovascular morbidity and mortality among postmenopausal women in the Women's Health Initiative study.

Authors:  Jordan W Smoller; Matthew Allison; Barbara B Cochrane; J David Curb; Roy H Perlis; Jennifer G Robinson; Milagros C Rosal; Nanette K Wenger; Sylvia Wassertheil-Smoller
Journal:  Arch Intern Med       Date:  2009-12-14

10.  Bupropion response on sleep quality in patients with depression: implications for increased cardiovascular disease risk.

Authors:  Preetam J Schramm; Russell E Poland; Uma Rao
Journal:  Eur Neuropsychopharmacol       Date:  2013-10-11       Impact factor: 4.600

View more
  4 in total

1.  Fluoxetine induces lipid metabolism abnormalities by acting on the liver in patients and mice with depression.

Authors:  Shu-Juan Pan; Yun-Long Tan; Shang-Wu Yao; Yu Xin; Xuan Yang; Jing Liu; Jing Xiong
Journal:  Acta Pharmacol Sin       Date:  2018-05-10       Impact factor: 6.150

2.  Factors Influencing the Cardiovascular Response to Subanesthetic Ketamine: A Randomized, Placebo-Controlled Trial.

Authors:  Thomas Liebe; Shijia Li; Anton Lord; Lejla Colic; Anna Linda Krause; Anil Batra; Moritz A Kretzschmar; Catherine M Sweeney-Reed; Gusalija Behnisch; Björn H Schott; Martin Walter
Journal:  Int J Neuropsychopharmacol       Date:  2017-11-01       Impact factor: 5.176

Review 3.  Psychological Responses to Acute Aerobic, Resistance, or Combined Exercise in Healthy and Overweight Individuals: A Systematic Review.

Authors:  Thomas J Elkington; Samantha Cassar; André R Nelson; Itamar Levinger
Journal:  Clin Med Insights Cardiol       Date:  2017-04-20

4.  Physical Activity and Body Composition Are Associated With Severity and Risk of Depression, and Serum Lipids.

Authors:  Claudia von Zimmermann; Merle Winkelmann; Tanja Richter-Schmidinger; Christiane Mühle; Johannes Kornhuber; Bernd Lenz
Journal:  Front Psychiatry       Date:  2020-06-05       Impact factor: 4.157

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.